We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Waiting times for autism diagnostic pathways based on referrals for suspected autism. By CCG, mental health service provider and split by age group.
This study aims to assess treatment outcomes among HIV–MultiDrug-Resistant -TB co-infected patients
Find out which services and goods relating to welfare are exempt from VAT, and if welfare services and goods that you provide can be exempt from VAT.
These tables set out the number and rate of children referred for an assessment for autism and the number and rate of children diagnosed with autism each quarter.
This annual report aims to show the prevalence rate of autism amongst the compulsory school age population.
The rules for ensuring patients’ referral to treatment (RTT) waiting time, for consultant-led treatment, is fair and consistent within an 18-week period.
Patients with recurring lymphoma, or who have not responded to prior treatments, could access a new bispecific antibody therapy to help treat their condition.
Implementation and Operational Research on children on ART between 2006 and 2010 in two clinics in Malawi
Chapters 6 and 7.
This is a Systematic Review and Meta-analysis
Systematic review and journal article
Aimed to determine prevalence and determinants of ART failure in those on first-line treatment
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).